Tin tức & Cập nhật

Treatment with isoniazid and rifapentine (HP) either for 1 month daily (1HP) or 3 months weekly (3HP) results in high rates of treatment success among people with a positive latent tuberculosis infection test and without HIV infection, a study has shown. The 3HP regimen has slightly lower rates of adverse reactions, but neither exhibits superiority to the other.

Real-world (RW) data presented at ASCO GU 2026 support the use of enfortumab vedotin plus pembrolizumab (EV+P) as frontline treatment for advanced urothelial carcinoma (UC).

A combination regimen comprising belzutifan and lenvatinib outdoes cabozantinib alone for the treatment of advanced clear cell renal cell carcinoma (ccRCC) in the phase III LITESPARK-011 study.